valopicitabine
Small moleculeexperimental
Valopicitabine (NM-283) is an antiviral drug which was developed as a treatment for hepatitis C, though only progressed as far as Phase III clinical trials. It acts as an RNA-dependent RNA polymerase inhibitor. It is a prodrug which is converted inside the body to the active form, 2'-C-methylcytidine triphosphate. — Wikipedia
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2003 (NCT00227435)
Timeline
Indications
Studied for
Mechanism of action
- RNA-directed RNA polymeraseINHIBITOR
RNA-directed RNA polymerase inhibitor
- Hepatitis C virusINHIBITOR
Hepatitis C virus inhibitor
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)[C@H](N)C(=O)O[C@@H]1[C@@H](CO)O[C@@H](n2ccc(N)nc2=O)[C@]1(C)O- Mol. weight
- 356.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL393820 ↗
- WikipediaValopicitabine ↗
- ChEMBLCHEMBL1743757 ↗
Also known as
- 2'-c-methylcytidine 3'-o-l-valinyl ester
- 2'-c-methylcytidine 3'-o-valinyl ester
- nm283
- nm283
- nm283
- nm 283
- nm-283
- talpha1
- valopicitabine
- valopicitabine
- valopicitabine
- valopicitabine
- valopicitabine
- valopicitabine dihydrochloride
- valopicitabine dihydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00395421 | Phase 2 | Oct 1, 2006 | Merck, Novartis |
| NCT00118768 | Phase 2 | Aug 1, 2005 | Merck |
| NCT00120861 | Phase 2 | Jan 1, 2005 | Merck |
| NCT00120835 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2004 | Merck |
| NCT00227435 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2003 | Merck |
Showing 5 of 5 trials
Page 1 / 1